Estimation Of Optimal Minimum Dosage Of Mycophenolate Mofetil In Children With Various Glomerular Diseases

Zhihong Lu,Haidong Fu,Lingfei Huang,Jingjing Wang,Caiyun Wang,Jianhua Mao
2018-01-01
Abstract:Background: Mycophenolate mofetil (MMF), a common immunosuppressant and a 2-ethyl ester derivative of mycophenolic acid (MPA),has exerted therapeutic efficacy in several kidney diseases. Here, we aimed to investigate the variation of MMF exposure in children with different glomerular diseases and estimate the optimal minimum dosage of MMF. Materials & methods: The serum MPA, the active compound of MMF, was measured in 57 children with primary nephrotic syndrome, Henoch Schonlein purpura nephritis, primary IgA nephropathy, or lupus nephritis. The MPA area under the curve over a 12 hour period (MPA-AUC(0-12h)) was calculated and its associations with the patients' clinical features were analyzed. Receiver operating characteristic curves were performed to explore the optimal minimum MMF dosage. Results: The average of MPA-AUC(0-12h) was 36.22 (14.38-91.47) mu g.h/mL. MAP-AUC(0-12h) of 39/57 patients was more than the target value (30 mu g.h/mL). The dose-normalized MPA-AUC(0-12) h was associated with plasma albumin but not with other clinical features. The ROC curves analyses indicated that area under the curve (AUC) in PNS was small (0.560) with a low sensitivity (28.6%) when evaluating the optimal minimum MMF dosage. In patients with HSPN, LN, or IgAN, the AUC was 0.829 with 64.0% sensitivity and 100% specificity and an optimal minimum MMF dosage of 588.2 mg/m(2) was obtained. Conclusions: MPA-AUC(0-12h) in PNS varied drastically in regard of MMF dose and should be monitored timely to adjust the MMF dosage while 588.2 mg/m(2) might be used as an optimal minimum dosage of MMF in children with LN, HSPN, or IgAN.
What problem does this paper attempt to address?